Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Manual and Self-Lymphatic Drainage Combined With Exercise in Women With Lipedema

NCT07803926 · tracked via the Priya Life Science Turkey tracker
Sponsor
Merve SEVINC GUNDUZ
Phase
Not applicable
Started
2026-08-25
Last updated
2026-09-10

Condition(s) studied

Lipedema

Investigational drug(s) / intervention(s)

Manual Lymphatic DrainageAerobic ExerciseSelf-Lymphatic DrainagePhysical Activity Guidance

Manual Lymphatic Drainage: Manual lymphatic drainage will be administered by a physiotherapist for approximately 30 minutes per session, twice weekly for 6 weeks. Slow, gentle, rhythmic manual techniques will be applied to facilitate lymphatic drainage.

Aerobic Exercise: Participants will perform supervised moderate-intensity treadmill-based aerobic exercise twice weekly for 6 weeks. Exercise intensity will be prescribed at 64-76% of maximum heart rate and monitored using the Borg Rating of Perceived Exertion Scale, targeting a score of 11-13.

Self-Lymphatic Drainage: Participants will be instructed by a physiotherapist on how to perform self-lymphatic drainage. They will perform the technique as part of their 6-week intervention program and will be regularly followed by the physiotherapist throughout the intervention period.

Physical Activity Guidance: Participants will receive guidance from a physiotherapist to engage in moderate-intensity physical activity during the 6-week intervention period. Walking intensity will be guided using the Talk Test, with participants instructed to maintain an intensity at which they can talk but not sing. Participants will be regularly followed throughout the intervention period.

Study summary

This randomized controlled study aims to compare the effects of two physiotherapy approaches in women with lipedema. Participants will be assigned to either manual lymphatic drainage combined with supervised aerobic exercise or self-lymphatic drainage combined with physical activity guidance. Both programs will be applied for six weeks. The study will investigate whether these two approaches differ in their effects on pain, lower extremity function, limb volume, mobility, quality of life, and depressive symptoms. Assessments will be performed before the intervention and at the end of the six-week program.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female sex. * Aged 18 to 65 years. * Diagnosed with lipedema. * Diagnosed with Stage I, II, III, or IV lipedema. * No participation in any physiotherapy program within the previous 3 months. * No previous liposuction surgery. * Not currently following a weight-loss diet. * No change in body weight greater than 10% within the previous 6 months. * Willing to participate in the study and provide informed consent. Exclusion Criteria: * Severe visual or cognitive impairment. * Severe cardiovascular disease. * Musculoskeletal conditions or injuries affecting the lower extremities, including osteoarthritis, contracture, or osteoporosis, that may interfere with participation in the study. * Skin conditions that may interfere with the intervention, such as pressure ulcers. * Uncontrolled endocrine disorders, including type 1 or type 2 diabetes mellitus or hypothyroidism. * Obesity secondary to endocrine disorders or medication-induced obesity. * Use of estrogen-progestin therapy within the previous 2 months. * Pregnancy or a positive pregnancy test. * Breastfeeding. * Concurrent participation in another clinical trial.

Primary outcome measure(s)

  • Pain Intensity — Baseline and 6 weeks
    Pain intensity will be assessed using the Visual Analog Scale (VAS). Participants will rate their pain on a 10-cm horizontal line ranging from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst/unbearable pain." Higher scores indicate greater pain intensity.

Trial sites (1)

FacilityCityRegionStatus
Bezmialem Vakif University Istanbul Eyupsultan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07803926 on ClinicalTrials.gov ↗ ← All trials in Turkey